IN VIVO ASSESSMENT OF CLINICALLY RELEVANT AUTOANTIBODIES IN IVIG PREPARATIONS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 在IVIG制剂中检测到自身抗体。理论上担心自身抗体可能对接受这些输注的患者造成损害，或导致IVIG患者的假阳性测试。 这是值得关注的，因为原发性免疫缺陷的患者在替代IVIG治疗，然后发展自身免疫性疾病可能与自身抗体水平进行评估。本研究旨在确定在没有临床自身免疫性疾病的原发性免疫缺陷患者中，IVIG输注后是否会增加自身抗体滴度。这些数据将有助于解释IVIG患者自身免疫性疾病的血清学试验。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Autoantibodies have been detected in IVIG preparations. There is a theoretical concern that autoantibodies could cause damage to patients receiving these infusions, or cause false positive tests in patients on IVIG. This is of concern because patients with primary immunodeficiency on replacement IVIG therapy who then develop autoimmune disease may be evaluated with autoantibody levels. This study aims to determine whether replacement IVIG infusions in patients with primary immundeficiency who do not have clinical autoimmune disease have increased autoantibody titers post-IVIG infusion. This data will aid in the interpretation of serologic tests for autoimmune disease in patients on IVIG.